Solid state of a new flavonoid derivative DA-6034

DA-6034 is a new synthetic flavonoid known to possess anti-inflammatory activity. The objective of this work was to investigate the existence of polymorphs and pseudopolymorphs of DA-6034. Six crystal forms, one hydrate form and five solvates, of DA-6034 have been isolated by recrystallization and characterized by differential scanning calorimetry (DSC), thermogravimetric analysis (TG), and powder X-ray diffractometry (PXRD). From the DSC and TG data it was confirmed that Form 1 is monohydrate; Form 2 is DMSO solvate; Form 3 is 1/2 DMSO solvate; Form 4 is 1/2 methyl ethyl ketone solvate; Form 5 is 1.5 H₂O, 1/2 acetic acid solvate; Form 6 is 1/2 H₂O, 1/4 butanol solvate. The PXRD patterns of the six crystal forms were different respectively. In the dissolution studies in pH 6.8 ± 0.05 buffer at 37 ± 0.5 °C, the solubility of solvates was higher than that of Form 1.     

Solid state of a new COX-2 inhibitor CG100649

CG100649 [4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide, polmacoxib, Acelex™] is a new NSAID used to treat osteoarthritis. It inhibits the enzymes carbonic anhydrase and COX-2. The objective of this work was to investigate the existence of polymorphs of CG100649 and the solubility of different crystal forms of CG100649. Four crystal forms of CG100649 (Forms 1–4) have been isolated by recrystallization and characterized by differential scanning calorimetry and powder X-ray diffractometry. In dissolution studies in pH 6.8 ± 0.05 buffer at 37 ± 0.5 °C, the solubility of Form 1 was the highest, and the dissolution rate at 30 min in water decreased in rank order: Form 3 > Form 2 > Form 4. After storage for one month at 2 °C and 24% relative humidity, all crystal forms were not transformed.

     

Solid state characterizations and analysis of stability in azelnidipine polymorphs

Azelnidipine, a new dihydropyridine calcium ion antagonist, was protected by patent in Japan. In present study, identifications of the crystal phases, including two polymorphic and a pseudopolymorphic crystal forms of azelnidipine, were attempted using powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), IR-, Raman-, THz-, and ss-NMR-spectroscopy. PXRD identified three different crystal forms, while, spectroscopy analysis provided the information of crystal structure involving intermolecular interactions. The transition thermodynamics of the azelnidipine polymorphs were extensively investigated by solubility method. The solubility of the two polymorphs of α and β in 50% ethanol at 25, 31, 37, 42, and 49°C was investigated; the values obtained were used to calculate the thermodynamic parameters of the transition reaction. The temperature of polymorphic phase transition in 50% ethanol was 50.78°C, and the values of ΔGα,β^θ, ΔHα,β^θ, and ΔSα,β^θ at 25°C were －1.18?kJ·mol^－1, －14.81?kJ·mol^－1, and －45.73?J·mol^－1·K^－1, respectively. Form β was proved to be thermodynamic stable form at room temperature and enantiotropically related with form α. The kinetics of the solid-state decomposition, studied using DSC analysis, showed that the activation energies of decomposition of the polymorphs α and β at high temperatures were 148.67 and 151.93?kJ·mol^－1.     

Polymorphic forms of bisoprolol fumarate

Bisoprolol fumarate is a beta blocker-type drug substance which has been well known for several decades. However, no relevant data can be found in the literature about its crystal polymorphism. The purpose of this paper was to present two anhydrous forms (Form I and Form II) and a hydrate of bisoprolol fumarate substance. Crystalline forms were studied by various solid-state analytical methods: Fourier transform infrared (FT-IR) spectroscopy, X-ray powder diffraction (XRPD), dynamic vapor sorption (DVS) and thermoanalytical methods (thermogravimetry and differential scanning calorimetry). Thermodynamic stability and solubility of the presented polymorphs were also investigated. Both FT-IR and XRPD methods were found to be suitable for the characterization of the different crystal structures. Thermoanalytical measurements showed that (1) Form I and Form II own clearly different melting points and (2) both Form II and hydrate forms can transform into Form I at higher temperature values. Results of the DVS measurements prove that both Form I and Form II became metastable under extremely humid conditions (>?80% RH) and converted into the hydrate. Thermodynamic stability studies showed that Form I and Form II polymorphs are in enantiotropic relationship with an enantiotropic point at about 40–45 °C. Solubility studies indicated that all of the prepared forms are highly soluble, and no difference was found between them. Considering the recommendations of the corresponding International Conference of Harmonization guideline, it can be stated that no specification is required for crystal polymorphism in case of this substance.

     

Preparation and physicochemical characterization of carbamazepine (CBMZ): para-sulfonated calix[n]arene inclusion complexes

The formation of inclusion complexes with para-sulfonated calix[n]arene (PSC[n]A) was studied for carbamazepine (CBMZ), a poorly water soluble anticonvulsant drug. The effect of PSC[4]A and PSC[6]A on aqueous solubility of carbamazepine was studied extensively. The complete complexation of the drug was achieved after 48 h of shaking with PSC[n]A in water and evaporation of water to get solid complex. The interaction between PSC[n]A and CBMZ in solid state inclusion complexes was accomplished by aqueous phase solubility studies, HPLC, DSC, PXRD, FTIR, UV–Vis, and FT-Raman spectroscopy. The solubility of CBMZ increases as a function of PSC[n]A concentration. The results of the two phase solubility experiments are in good conformity to signify the formation of 1:1 (PSC[6]A:CBMZ) and 2:1 PSC[4]A:CBMZ complexes. The order of dissolution rate of CBMZ is inclusion complex > physical mixture > drug alone. The purpose of this study was to enhance solubility resulting in high dissolution rate and bioavailability of this essentially water insoluble drug.     

Preparation,Characterization and ex vivo Intestinal Permeability Studies of Ibuprofen Solid Dispersion

The aim of the present study was to improve the solubility and dissolution rate of ibuprofen and to evaluate, ex vivo, the intestinal permeation. Solid dispersions (SD) were prepared with Kollicoat IR^® by solvent evaporation technique in different drug:carrier ratios. The permeation intestinal of ibuprofen was evaluated by inverted intestinal sac method. The SD was characterized by solubility equilibrium, FT-IR, DSC, PXRD, SEM, and dissolution rate. The solubility, dissolution rate, and permeability were significantly greater for SD 1:2. The PXRD, SEM and DSC indicated a partial change in the crystalline state of ibuprofen. The solubility equilibrium of SD (1:2) was approximately 15 times greater than the solubility of ibuprofen. Dissolution rate enhancement was attributed to the decreased crystallinity of the ibuprofen, and increase of wettability and decrease of particle size. In conclusion, dissolution rate and intestinal permeability of ibuprofen were enhanced by the use of Kollicoat IR^® carrier in the SD formulation.     

Multicomponent solid forms of the uric acid reabsorption inhibitor lesinurad and cocrystal polymorphs with urea: DFT simulation and solubility study

Lesinurad (systematic name: 2‐{[5‐bromo‐4‐(4‐cyclopropylnaphthalen‐1‐yl)‐4H‐1,2,4‐triazol‐3‐yl]sulfanyl}acetic acid, C₁₇H₁₄BrN₃O₂S) is a selective uric acid reabsorption inhibitor related to gout, which exhibits poor aqueous solubility. High‐throughput solid‐form screening was performed to screen for new solid forms with improved pharmaceutically relevant properties. During polymorph screening, we obtained two solvates with methanol (CH₃OH) and ethanol (C₂H₅OH). Binary systems with caffeine (systematic name: 3,7‐dihydro‐1,3,7‐trimethyl‐1H‐purine‐2,6‐dione, C₈H₁₀N₄O₂) and nicotinamide (C₆H₆N₂O), polymorphs with urea (CH₄N₂O) and eutectics with similar drugs, like allopurinol and febuxostat, were prepared using the crystal engineering approach. All these novel solid forms were confirmed by XRD, DSC and FT–IR. The crystal structures were solved by single‐crystal and powder X‐ray diffraction. The crystal structures indicate that the lesinurad molecule is highly flexible and the triazole moiety, along with the rotatable thioacetic acid (side chain) and cyclopropane ring, is almost perpendicular to the planar naphthalene moiety. The carboxylic acid–triazole heterosynthon in the drug is interrupted by the presence of methanol and ethanol molecules in their crystal structures and forms intermolecular macrocyclic rings. The caffeine cocrystal maintains the consistency of the acid–triazole heterosynthons as in the drug and, in addition, they are bound by several auxiliary interactions. In the binary system of nicotinamide and urea, the acid–triazole heterosynthon is replaced by an acid–amide synthon. Among the urea cocrystal polymorphs, Form I (P, 1:1) consists of an acid–amide (urea) heterodimer, whereas in Form II (P2₁/c, 2:2), both acid–amide heterosynthons and urea–urea dimers co‐exist. Density functional theory (DFT) calculations further support the experimentally observed synthon hierarchies in the cocrystals. Aqueous solubility experiments of lesinurad and its binary solids in pH 5 acetate buffer medium indicate the apparent solubility order lesinurad–urea Form I (43‐fold) > lesinurad–caffeine (20‐fold) > lesinurad–allopurinol (12‐fold) ? lesinurad–nicotinamide (11‐fold) > lesinurad, and this order is correlated with the crystal structures.     

Use of isothermal microcalorimetry in pharmaceutical preformulation studies,Part I. Monitoring crystalline phase transitions

Solid-state transformation kinetics of two crystal forms of a synthetic tetrapeptide was monitored by isothermal microcalorimetry and complementary solid-state analytical techniques. Form B, the crystal form obtained from the synthetic process transformed to Form D upon exposure to higher relative humidity conditions (>60% RH). The transformation occurred rapidly at higher temperature, and relative humidities. An intermediate phase of very low crystallinity (amorphous-like phase) was observed when transformation was slow. Form D was observed to be physically stable at higher relative humidities and thus the preferred crystal form for development. Exposure of Form B to high relative humidity was the only process through which Form D was obtained. Optimal conditions for transformation of Form B to Form D were determined by microcalorimetric experiments and were used for larger scale processing of Form B to Form D.     

Polymorphic Characterization,Pharmacokinetics, and Anti-Inflammatory Activity of Ginsenoside Compound K Polymorphs

Polymorphism exhibits different physicochemical properties, which can impact the bioavailability and bioactivity of solid drugs. This study focused on identifying the polymorphs of ginsenoside compound K (CK) and studying their different behaviors in pharmacokinetics (PK) and pharmacodynamics (PD). Four CK polymorphs (form I, II, III, and IV) from organic solvents were characterized by scanning electron microscope (SEM), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), and powder X-ray diffraction (PXRD). A feasible LC-MS/MS method was exploited to determine the PK parameters. Form II displayed the most exposure, followed by form I, III, and IV. Notably, all forms showed sex dimorphism, and the bioavailability in the female group was about two-fold higher than in the male group. The PD properties were investigated in carrageenan-induced acute paw inflammation, and form II at 20 mg/kg showed significant inhibition of edema by 42.7%. This study clarified the polymorphic, PK, and PD characters of four crystal forms of CK, and the data suggested that form II had the best efficacy for drug development.     

Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design,Development, and In Vitro Characterization

Irbesartan (IR) is an angiotensin II receptor antagonist drug with antihypertensive activity. IR bioavailability is limited due to poor solubility and first-pass metabolism. The current investigation aimed to design, develop, and characterize the cyclodextrin(s) (CD) complexed IR (IR-CD) loaded solid lipid nanoparticles (IR-CD-SLNs) for enhanced solubility, sustained release behavior, and subsequently improved bioavailability through oral administration. Based on phase solubility studies, solid complexes were prepared by the coacervation followed by lyophilization method and characterized for drug content, inclusion efficiency, solubility, and in vitro dissolution. IR-CD inclusion complexes demonstrated enhancement of solubility and dissolution rate of IR. However, the dissolution efficiency was significantly increased with hydroxypropyl-βCD (HP-βCD) inclusion complex than beta-CD (βCD). SLNs were obtained by hot homogenization coupled with the ultrasonication method with IR/HP-βCD inclusion complex loaded into Dynasan 112 and glycerol monostearate (GMS). SLNs were evaluated for physicochemical characteristics, in vitro release, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and physical stability at room temperature for two months. The optimized SLNs formulation showed particle size, polydispersity index, zeta potential, assay, and entrapment efficiency of 257.6 ± 5.1 nm, 0.21 ± 0.03, −30.5 ± 4.1 mV, 99.8 ± 2.5, and 93.7 ± 2.5%, respectively. IR-CD-SLN and IR-SLN dispersions showed sustained release of IR compared to the IR-CD inclusion complexes. DSC results complimented PXRD results by the absence of IR endothermic peak. Optimized IR-CD complex, IR-SLN, and IR-CD-SLN formulations were stable for two months at room temperature. Thus, the current IR oral formulation may exhibit improved oral bioavailability and prolonged antihypertensive activity, which may improve therapeutic outcomes in the treatment of hypertension and heart failure.     

Thermodynamic Analysis of DSC Data for Acetaminophen Polymorphs

This article provides a thermodynamic analysis of DSC data for acetaminophen polymorphic forms I and II by measurement of heat capacity. Form I is found to have lower heat capacity and free energy and hence better stability than Form II down to at least –30°C. The transition temperature below which Form II becomes more stable was determined to be less than –120°C. Form I is more stable than Form II as a consequence of its higher entropy, since its crystallographic packing arrangement is of larger energy. This revised version was published online in August 2006 with corrections to the Cover Date.     

Polymorphism and stability of norfloxacin, (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinil)-3-quinolinocarboxylic acid

Norfloxacin was studied by thermal methods (TG and DSC), X-ray powder diffraction, and by FT-IR, UV-VIS and NMR spectroscopy. The drug substance can be prepared in two different crystalline forms and in amorphous state, depending on the experimental conditions of preparation. DSC examinations were carried out at various heating rates and by cycling the samples in the temperature range 50°–250°C. The unstable crystalline form undergoes two irreversible solid-solid phase transitions at 176.5° and 197.6°C. The polymorph melts in the temperature range 218.5°–220.0°C.

---

Zusammenfassung Norfloxacin wurde mittels thermischer Methoden (TG und DSC), weiterhin mittels der Debye-Scherrer-Methode und FTIR-, UV-VIS-und NMR-Spektroskopie untersucht. Je nach den experimentellen Bedingungen bei der Herstellung kann die Wirkstoffsubstanz in zwei verschiedenen kristallinen und in einer amorphen Form hergestellt werden. Die DSC-Untersuchungen wurden bei zahlreichen Aufheizgeschwindigkeiten und durch abwechselnden Temperaturwechsel zwischen Raum- und Schmelztemperatur durchgeführt. Die unstabile kristalline Form unterliegt zwei irreversiblen Feststoff-Feststoff-Umwandlungen bei 176.5° und bei 195.6°C. Das polymorphe Material schmilzt im Temperaturbereich 218.5°–220.0°C.

     

Triclabendazole: An Intriguing Case of Co‐existence of Conformational and Tautomeric Polymorphism

The crystal polymorphism of the anthelmintic drug, triclabendazole ( TCB ), is described. Two anhydrates (Forms I and II), three solvates, and an amorphous form have been previously mentioned. This study reports the crystal structures of Forms I ( 1 ) and II ( 2 ). These structures illustrate the uncommon phenomenon of tautomeric polymorphism. TCB exists as two tautomers A and B. Form I (Z′=2) is composed of two molecules of tautomer A while Form II (Z′=1) contains a 1:1 mixture of A and B. The polymorphs are also characterized by using other solid‐state techniques (differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), PXRD, FT‐IR, and NMR spectroscopy). Form I is the higher melting form (m.p.: 177 °C, ΔH_f=≈105±4 J g^?1) and is the more stable form at room temperature. Form II is the lower melting polymorph (m.p.: 166 °C, ΔH_f=≈86±3 J g^?1) and shows high kinetic stability on storage in comparison to the amorphous form but it transforms readily into Form I in a solution‐mediated process. Crystal structure analysis of co‐crystals 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 further confirms the existence of tautomeric polymorphism in TCB . In 3 and 11 , tautomer A is present whereas in 4 , 5 , 6 , 7 , 8 , 9 , 10 the TCB molecule exists wholly as tautomer B. The DFT calculations suggest that the optimized tautomers A and B have nearly the same energies. Single point energy calculations reveal that tautomer A (in Form I) exists in two low‐energy conformations, whereas in Form II both tautomers A and B exist in an unfavorable high‐energy conformation, stabilized by a five‐point dimer synthon. The structural and thermodynamic features of 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 are discussed in detail. Triclabendazole is an intriguing case in which tautomeric and conformational variations co‐exist in the polymorphs.     

Polymorphism and solvatomorphism of bicalutamide

Single crystals of the crystallosolvate [bicalutamide + DMSO] with 1:1 stoichiometry were grown, and their structures were solved by X-ray diffraction methods. Polymorphic modifications I and II, the amorphous state, and the DMSO crystallosolvate of bicalutamide were prepared and thermochemistry of fusion processes was studied by DSC technique. The temperature dependence of the saturated vapor pressure of polymorphic form I was obtained and the thermodynamic characteristics of the sublimation process including the crystal lattice energy were calculated. The solution enthalpies of the forms under consideration and the crystallosolvate were acquired by the solution calorimetry procedure. The phase transition enthalpies estimated for form I, form II, and the amorphous state followed the rank order: form I— > form II, form I— > amorphous state, and form II— > amorphous state. The crystal lattice energy of polymorphic form II was determined using the results of sublimation and solution calorimetric experiments. The difference between the crystal lattice energy of the crystallosolvate and unsolvated phases was observed. The dissolution kinetics of forms I, II, the amorphous state, and DMSO solvate in water were investigated.     

Thermal and structural characterization of two polymorphs of the bronchodilator tulobuterol

Two polymorphs of the bronchodilator tulobuterol (2-chloro-α-[[(1,1-dimethylethyl)- amino]-methyl]benzenemethanol) with melting points differing by ~10 K were isolated and characterized by thermal analysis (HSM, TG, DSC), as well as powder and single crystal X-ray diffraction. Analysis of melting data for Forms 1 and 2 revealed a monotropic relationship, with ΔG ₀, the Gibbs free energy difference at the melting temperature of the lower melting form, less than 1 kJ mol^-1. This small difference is reconciled with known structural features in the crystals of the two forms. The hydrogen bonding capacity of the tulobuterol molecule is fully utilised in both polymorphs in forming a common trimeric unit via three strong O-H···N interactions. Consequently only weak intermolecular forces characterize the packing of the trimers in the monoclinic polymorph (Form 1, P2₁/n, Z =12) and the triclinic polymorph (Form 2, P(-1),Z =6). This revised version was published online in July 2006 with corrections to the Cover Date.     

Some Physico-chemical Properties of Doxazosin Mesylate Polymorphic Forms and its Amorphous State

Seven polymorphic modifications of doxazosin mesylate, designed as forms A, D, E, F, G, H, I, and the amorphous state were studied by thermal methods (TG and DSC), temperature resolved X-ray powder diffractometry, hot stage and scanning electron microscopy and by FT-IR spectroscopy. Amorphous form was obtained either by fast evaporation of the solvent or by fast cooling of the melt in the DSC. Polymorphs A and F were found to be stable in the temperature range from room temperature to their melting points at 277.9 and 276.5°C, respectively. Form G, which melts at 270.8°C, was found to be hygroscopic. Polymorph D undergoes irreversible solid–liquid–solid phase transition at 235.5°C to polymorph I which melts at 274.9°C. Form H, which melts at 258.0°C, was found to be unstable at high temperatures. DSC examinations revealed that form H is irreversibly transformed to polymorph F during heating above the temperature of about 240°C. The amorphous state was found to be stable at room temperature but when heating above the glass transition (T _g=144.1°C) it crystallizes at 221.6°C, what leads into a mixture of polymorphic forms. The new polymorphic form designed as E was identified in the mixture. The polymorph E is converted by heating to the more stable form F. The solubilities at 25°C for forms A, and F in methanol are 3.5 and 7.7 mg mL⁻¹and in water they are 3.8 and 6.2 mg mL⁻¹, respectively. This revised version was published online in August 2006 with corrections to the Cover Date.     

Amorphous Form of Carvedilol Phosphate—The Case of Divergent Properties

The amorphous form of carvedilol phosphate (CVD) was obtained as a result of grinding. The identity of the obtained amorphous form was confirmed by powder X-ray diffraction (PXRD), different scanning calorimetry (DSC), and FT-IR spectroscopy. The process was optimized in order to obtain the appropriate efficiency and time. The crystalline form of CVD was used as the reference standard. Solid dispersions of crystalline and amorphous CVD forms with hydrophilic polymers (hydroxypropyl-β-cyclodextrin, Pluronic^® F-127, and Soluplus^®) were obtained. Their solubility at pH 1.2 and 6.8 was carried out, as well as their permeation through a model system of biological membranes suitable for the gastrointestinal tract (PAMPA-GIT) was established. The influence of selected polymers on CVD properties was defined for the amorphous form regarding the crystalline form of CVD. As a result of grinding (four milling cycles lasting 15 min with 5 min breaks), amorphous CVD was obtained. Its presence was confirmed by the “halo effect” on the diffraction patterns, the disappearance of the peak at 160.5 °C in the thermograms, and the changes in position/disappearance of many characteristic bands on the FT-IR spectra. As a result of changes in the CVD structure, its lower solubility at pH 1.2 and pH 6.8 was noted. While the amorphous dispersions of CVD, especially with Pluronic^® F-127, achieved better solubility than combinations of crystalline forms with excipients. Using the PAMPA-GIT model, amorphous CVD was assessed as high permeable (Papp > 1 × 10⁻⁶ cm/s), similarly with its amorphous dispersions with excipients (hydroxypropyl-β-cyclodextrin, Pluronic^® F-127, and Soluplus^®), although in their cases, the values of apparent constants permeability were decreased.     

Reassessment of paracetamol orthorhombic Form III and determination of a novel low‐temperature monoclinic Form III‐m from powder diffraction data

Paracetamol [N‐(4‐hydroxyphenyl)acetamide, C₈H₉NO₂] has several polymorphs, just like many other drugs. The most stable polymorphs, denoted Forms I and II, can be obtained easily and their crystal structures are known. Crystals of the orthorhombic, less stable, room‐temperature Form III are difficult to grow; they need a special recipe to crystallize and suffer from severe preferred orientation. A crystal structure model of Form III has been proposed and solved from a combination of structure prediction and powder X‐ray diffraction (PXRD) [Perrin et al. (2009). Chem. Commun. 22 , 3181–3183]. The final R_wp value of 0.138 and the corresponding considerable residual trace were reasons to check its validity. A new structure determination of Form III using new high‐resolution PXRD data led to a final R_wp value of 0.042 and an improvement of the earlier proposed model. In addition, a reversible phase transition was found at 170–220 K between the orthorhombic Form III and a novel monoclinic Form III‐m. The crystal structure of Form III‐m has been determined and refined from PXRD data to a final R_wp value of 0.059.     

Crystal forms of an angiotensin II receptor antagonist BR-A657

The compound BR-A657 is an angiotensin II receptor antagonist. The objective of this work was to investigate the existence of polymorphs and pseudopolymorphs of BR-A657 and the transformation of crystal forms. Three crystal forms of BR-A657 have been isolated by recrystallization and characterized by powder X-ray diffractometry, differential scanning calorimetry, and thermogravimetric analysis. After storage of three days at 0% RH (silica gel, 20°C), 52% RH (saturated solution of Na₂Cr₂O₇·2H₂O/20°C) and 95% RH (saturated solution of Na₂HPO₄/20°C), Forms 2 and 3 were transformed to Form 1.     

The effect of water molecule on the thermal stability of lanthanide compounds with 1,3-benzeneditetrazol-5-yl

Six lanthanide compounds [Ln(H₂O)₉](m-BDTH)₃·9(H₂O) where Ln = La (1), and [Ln(H₂O)₈](m-BDTH)₃·9(H₂O) (m-BDTH₂ = 1,3-benzeneditetrazol-5-yl) where Ln = Lu (2), Yb (3), Er (4), Ho (5) and Y (6) were hydrothermally synthesized and characterized by elemental analyses, infrared spectra, powder X-ray diffraction (PXRD) and X-ray single crystal diffraction. PXRD indicates that 2–6 are isomorphous. Structural analyses reveal that 1 is coordinated by nine water molecules forming a capped-square antiprism, while 2–6 are coordinated by eight water molecules forming a simple square antiprismatic geometry. Effects of water molecules on thermal stability were also discussed by thermogravimetric (TG), DSC, and PXRD under different temperatures. TG analyses suggest that 1 loses lattice and coordinated water molecules with no diacritical boundary, and 6 removes lattice water molecules first and then coordinated water molecules. DSC and PXRD further confirm the consequence.